4th Modern Drug Discovery and Development Summit

GTCbio is announcing it's 4th Modern Drug Discovery & Development Summit (M3D) taking place on October 15-17, 2008 in San Diego, CA.

This comprehensive summit offers an in-depth, 360 degree look into the drug discovery and development process. With over 150 speakers at 6 full tracks, 6 mini sessions, 3 short symposia, plenary keynote presentations, poster presentations, and dedicated networking sessions, the summit places its attendees in the midst of industry's greats minds to engage in collaborations, new ideas and problem solving.

The goal of the summit is to provide a forum for critical discussion to advance the understanding of the drug discovery and development field.

Submit an Abstract by July 31, 2008 and have the chance to give an oral presentation!

Register and save up to $500 by August 15, 2008!

Conference Highlights

Tracks

Biological Therapeutics
Translational Medicine
Biotech & Pharma Partnering & Licensing
Drug Design & Lead Discovery
Emerging Targets & Therapeutics
Pharmacokinetics/Pharmacodynamics
Leading speakers

Short Symposia

Stem Cells as Tools for Drug Discovery
Imaging Technologies
Regulations & Policy in Drug Discovery

Mini Sessions

Genetics & Genomics in Drug Discovery & Development
Combination Therapeutics
Salvaging Compounds from Drug Attrition
Humanized Mice
In Silico Modeling in Biosystems

Biological Therapeutics

Modern Vaccine Development
Targeted Biologics: Antibodies & Beyond
Immunogenicity & Hummanization
Novel Protein & Peptide Theraputics
Drug Delivery Technologies

________________________________________________________________________________________________

Translational Medicine

Target Identification
Target Validation
Maximizing Safety and Efficacy
Toxicology & Safety
Moving from Lab to Clinic

________________________________________________________________________________________________

Biotech & Pharma Partnering & Licensing

Tools for Success Partnering
Alternative Financing
Panel Licensing in Oncology & CNS
Alliance management & Types of Partnerships
Patents, Outsourcing & Contract Res.

________________________________________________________________________________________________

Drug Design & Lead Discovery

Screening & hit Identification
Hit to Lead
Lead Optimization I
Lead Optimization II
Data Management

________________________________________________________________________________________________

Emerging Targets & Therapeutics

Choosing & Validating a Target
Oncology
CNS Diseases
Infectious & Metabolic Diseases
Inflammatory Pathways

________________________________________________________________________________________________

Pharmacokinetics / Pharmacodynamics

CNS Pharmacokinetics Issues
Oncology Pharmacokinetics Issues
Pharmacokinetics Relationships for Small Molecule vs. Pharmacokinetics relationship Antibody Therapies
Pharmacokinetics/Pharmacodynamics Analysis for Small Molecule indications vs. Antibody Indications
Quantitative Pharmacokinetics/Pharmacodynamics Analysis in Drug Development

Click here for a full agenda.

________________________________________________________________________________________________

Leading Speakers

Gordana Apic
Chairman
Cambridge Cell Networks Ltd

Heather Arnett
Amgen, Inc.

Steven Bartz
Research Fellow
Merck & Co.

Kirk Bertelsen
Sr. PK/PD Leader, Clinical Pharmacokinetics and Experimental Medicine
Johnson & Johnson

Doug Cole
Vice President Drug Discovery
Affymax

Allen J. Duplantier
Associate Research Fellow
Pfizer Global R&D

James Dykens
Senior Principal Scientist
Pfizer Global R&D

Sandhya Girish
Late Stage Pharmacokinetics and Pharmacodynamics
Genentech, Inc.

Debraj GuhaThakurta
Merck & Co.

Hovhannes Gukasyan
Pfizer Global R&D

Gilles Hanton
Toxicology and Comparative Medicine
Pfizer

Randolf Kerschbaumer
Manager Molecular Biology
Baxter BioScience

Gilles Hanton
Toxicology and Comparative Medicine
Pfizer

Randolf Kerschbaumer
Manager Molecular Biology
Baxter BioScience

Daniel Lee
Project Team Leader
Biogen Idec

Xing-Rong Liu
Pharmacokinetics, Dynamics and Metabolism
Roche

Mark Ma
Amgen Inc.

Brian MacDonald
CEO
Zelos Pharmaceuticals

Edward Maggio
President & CEO
Aegis Therapeutics LLC

Bimal Malhotra
Director, Global Clinical Pharmacology
Pfizer, Inc.

Mathai Mammen
Vice President, Molecular & Cellular Biology
Theravance, Inc.

Shane Marine
Merck Research Laboratories

Huseyin Mehmet
Director, Apoptosis Research
Merck & Co.

Nayan Nanavati
Vice President
PAREXEL International Corporation

Linh Nguyen
Exelixis

Dr. Christopher Rhodes
Senior Director Drug Delivery
Amylin Pharmaceuticals

Chris Shaffer
PK/PD & Metabolism
Pfizer Global R&D

Lauren Sherman
Merck & Co.

Indresh Srivastava
Novartis

Jean-Philliipe Stephan
Research Scientist
Genentech, Inc.

Walter Strapps
Merck & Co.

Paul Thompson
Senior Legal Director, Licensing
Schering-Plough Pharmaceuticals

Mark Throsby
Project Director, Antibody Discovery
Crucell

Qin Wang
Biogen Idec

Yael Weiss
Director, Licensing & External Research
Merck Research Laboratories

Christopher Winrow
Merck Research Laboratories

Jeff Wiseman
Vice President, Technology & Corporate Development
Locus Pharmaceuticals

Josh Xiao
Amgen

Chunhui Xu
Group Leader
Geron

Ming Yu
Bristol Myers-Squibb

Sponsored in part by:

Conference Partners: